OTC · CIK 0000732417
HBIA HILLS BANCORPORATION
Insider trading from SEC Form 4. Last filing 7 d ago.
HILLS BANCORPORATION (HBIA) has 15 SEC Form 4 filings on file from 6 insiders, the latest filed on Oct 6, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at HILLS BANCORPORATION, scored.
Transactions
Every row filed, 15 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Brian R. Globokar SVP, Dr of Trust & Wealth Mgmt | AGrant or award Common Stock | +56 | $40.50 | $2,250 | 7,663 | 7 d ago |
| Oct 2, 2026 | Lisa A Shileny President and CEO | AGrant or award Common Stock | +56 | $40.50 | $2,250 | 18,724 | 7 d ago |
| Oct 2, 2026 | Anthony Roetlin V SVP Chief Financial Officer | AGrant or award Common Stock | +56 | $40.50 | $2,250 | 6,933 | 7 d ago |
| Oct 2, 2026 | Kenza Bemis Nelson SVP, General Counsel | AGrant or award Common Stock | +42 | $40.50 | $1,701 | 6,775 | 7 d ago |
| May 12, 2026 | Roger K Smith director | AGrant or award Stock Optionsderivative | +1,371 | $87.50 | $120k | 1,371 | May 13, 2026 |
| Apr 1, 2026 | Brian R. Globokar SVP, Dr of Trust & Wealth Mgmt | AGrant or award Common Stock | +31 | $73.35 | $2,250 | 3,775 | Apr 3, 2026 |
| Apr 1, 2026 | Lisa A Shileny President and CEO | AGrant or award Common Stock | +31 | $73.35 | $2,250 | 9,306 | Apr 3, 2026 |
| Apr 1, 2026 | Anthony Roetlin V SVP Chief Financial Officer | AGrant or award Common Stock | +31 | $73.35 | $2,250 | 3,410 | Apr 3, 2026 |
| Jan 13, 2026 | Timothy D Finer SVP, Director of Comml Banking | AGrant or award Common Stock | +400 | $81.50 | $33k | 9,300 | Apr 2, 2026 |
| Jul 3, 2025 | Brian R. Globokar SVP, Dr of Trust & Wealth Mgmt | AGrant or award Common Stock | +33 | $67.50 | $2,250 | 4,159 | Jul 7, 2025 |
| Jul 3, 2025 | Lisa A Shileny President and CEO | AGrant or award Common Stock | +33 | $67.50 | $2,250 | 7,362 | Jul 7, 2025 |
| Jul 3, 2025 | Anthony Roetlin V SVP Chief Financial Officer | AGrant or award Common Stock | +33 | $67.50 | $2,250 | 2,880 | Jul 7, 2025 |
| Apr 3, 2025 | Brian R. Globokar SVP, Dr of Trust & Wealth Mgmt | AGrant or award Common Stock | +35 | $64.80 | $2,250 | 4,125 | Apr 4, 2025 |
| Apr 3, 2025 | Lisa A Shileny President and CEO | AGrant or award Common Stock | +35 | $64.80 | $2,250 | 7,329 | Apr 4, 2025 |
| Apr 3, 2025 | Anthony Roetlin V SVP Chief Financial Officer | AGrant or award Common Stock | +35 | $64.80 | $2,250 | 2,847 | Apr 4, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Timothy D FinerSVP, Director of Comml Banking
- Brian R. GlobokarSVP, Dr of Trust & Wealth Mgmt
- Kenza Bemis NelsonSVP, General Counsel
- Anthony Roetlin VSVP Chief Financial Officer
- Lisa A ShilenyPresident and CEO
- Roger K Smithdirector
Questions about HBIA
Answered from the filings on this page, as of the latest one.
Are insiders buying HBIA?
No. In the last 90 days no insider at HILLS BANCORPORATION bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade HBIA on the open market?
No open-market trade has been scored at HILLS BANCORPORATION. The latest Form 4 on file was filed on Oct 6, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at HILLS BANCORPORATION?
6 people have filed a Form 4 at HILLS BANCORPORATION, among them Timothy D Finer (SVP, Director of Comml Banking), Brian R. Globokar (SVP, Dr of Trust & Wealth Mgmt), Kenza Bemis Nelson (SVP, General Counsel). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.